Impact of 1q gains on treatment outcomes of patients with newly diagnosed multiple myeloma in a real-world Swedish population receiving modern treatment
Lemonakis, Konstantinos LU ; Olsson-Arvidsson, Linda LU ; Karlsson, Conny ; Johansson, Bertil LU and Hansson, Markus LU
(2023)
In European Journal of Haematology
111(3).
p.391-399
- Abstract
Background: Amplification of 1q (amp(1q); ≥4 1q copies) has repeatedly been reported to predict a worse outcome in multiple myeloma (MM), whereas the impact of gain of 1q (gain(1q); three 1q copies) is less clear. Methods: We investigated survival of MM in relation to amp(1q) and gain(1q) by retrospectively analysing 346 consecutively newly diagnosed MM (NDMM) patients. Of these, 62 (18%) had amp(1q), 97 (28%) gain(1q) and 187 (54%) a normal number of 1q copies (no1q). Results: The patients with amp(1q) had a shorter median progression-free survival than those with gain(1q) or no(1q) (13.1 months, 95% confidence interval [CI] 8.2–18.1 months vs. 36.1 months, 95% CI 23.1–49.1 months vs. 25.4 months, 95% CI 19.8–31.1 months, p =.005). The... (More)
Background: Amplification of 1q (amp(1q); ≥4 1q copies) has repeatedly been reported to predict a worse outcome in multiple myeloma (MM), whereas the impact of gain of 1q (gain(1q); three 1q copies) is less clear. Methods: We investigated survival of MM in relation to amp(1q) and gain(1q) by retrospectively analysing 346 consecutively newly diagnosed MM (NDMM) patients. Of these, 62 (18%) had amp(1q), 97 (28%) gain(1q) and 187 (54%) a normal number of 1q copies (no1q). Results: The patients with amp(1q) had a shorter median progression-free survival than those with gain(1q) or no(1q) (13.1 months, 95% confidence interval [CI] 8.2–18.1 months vs. 36.1 months, 95% CI 23.1–49.1 months vs. 25.4 months, 95% CI 19.8–31.1 months, p =.005). The 3-year overall survival (OS) was 56% for amp(1q), 76% for gain(1q) and 80% for no1q (p =.003). In the multivariate analysis, the presence of amp(1q) was independently associated with a shorter OS (hazard ratio 1.99, 95% CI 1.03–3.82, p =.039), whereas gain(1q) had no negative effect on survival. Conclusion: Our results thus suggest that amp(1q) should be considered a high-risk abnormality in NDMM and that new treatment strategies should be explored to mitigate its negative effect on survival.
(Less)
- author
- Lemonakis, Konstantinos
LU
; Olsson-Arvidsson, Linda
LU
; Karlsson, Conny
; Johansson, Bertil
LU
and Hansson, Markus
LU
- organization
- publishing date
- 2023-09
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- gain of 1q, multiple myeloma, survival
- in
- European Journal of Haematology
- volume
- 111
- issue
- 3
- pages
- 9 pages
- publisher
- Wiley-Blackwell
- external identifiers
-
- pmid:37271732
- scopus:85161404969
- ISSN
- 0902-4441
- DOI
- 10.1111/ejh.14018
- language
- English
- LU publication?
- yes
- id
- 1f92834e-1b6d-41ab-8701-614ef254dcc9
- date added to LUP
- 2023-08-23 13:44:57
- date last changed
- 2024-04-20 01:21:08
@article{1f92834e-1b6d-41ab-8701-614ef254dcc9,
abstract = {{<p>Background: Amplification of 1q (amp(1q); ≥4 1q copies) has repeatedly been reported to predict a worse outcome in multiple myeloma (MM), whereas the impact of gain of 1q (gain(1q); three 1q copies) is less clear. Methods: We investigated survival of MM in relation to amp(1q) and gain(1q) by retrospectively analysing 346 consecutively newly diagnosed MM (NDMM) patients. Of these, 62 (18%) had amp(1q), 97 (28%) gain(1q) and 187 (54%) a normal number of 1q copies (no1q). Results: The patients with amp(1q) had a shorter median progression-free survival than those with gain(1q) or no(1q) (13.1 months, 95% confidence interval [CI] 8.2–18.1 months vs. 36.1 months, 95% CI 23.1–49.1 months vs. 25.4 months, 95% CI 19.8–31.1 months, p =.005). The 3-year overall survival (OS) was 56% for amp(1q), 76% for gain(1q) and 80% for no1q (p =.003). In the multivariate analysis, the presence of amp(1q) was independently associated with a shorter OS (hazard ratio 1.99, 95% CI 1.03–3.82, p =.039), whereas gain(1q) had no negative effect on survival. Conclusion: Our results thus suggest that amp(1q) should be considered a high-risk abnormality in NDMM and that new treatment strategies should be explored to mitigate its negative effect on survival.</p>}},
author = {{Lemonakis, Konstantinos and Olsson-Arvidsson, Linda and Karlsson, Conny and Johansson, Bertil and Hansson, Markus}},
issn = {{0902-4441}},
keywords = {{gain of 1q; multiple myeloma; survival}},
language = {{eng}},
number = {{3}},
pages = {{391--399}},
publisher = {{Wiley-Blackwell}},
series = {{European Journal of Haematology}},
title = {{Impact of 1q gains on treatment outcomes of patients with newly diagnosed multiple myeloma in a real-world Swedish population receiving modern treatment}},
url = {{http://dx.doi.org/10.1111/ejh.14018}},
doi = {{10.1111/ejh.14018}},
volume = {{111}},
year = {{2023}},
}